GUIDO MAGNI

Guido Magni, MD, PhD, serves as a distinguished Managing Director at Versant Ventures, a leading venture capital firm dedicated to investing in and building innovative healthcare companies. With a profound background in global drug development and clinical research, Dr. Magni plays a pivotal role in identifying promising early-stage biotechnology companies and guiding their growth from concept to clinical success. His expertise is instrumental in shaping Versant's strategy for creating impactful therapeutic solutions.

Before joining Versant Ventures in 2015, Dr. Magni accumulated a wealth of experience in the pharmaceutical industry, holding significant leadership positions at major global companies. Notably, he served as Senior Vice President and Global Head of Development at Roche, where he oversaw a broad portfolio of drug development programs. Prior to Roche, he held the role of Vice President and Head of Global Clinical Development at Merck Serono and earlier at Serono, contributing to the advancement of numerous therapeutic candidates through various clinical stages. This extensive career trajectory, spanning over two decades in drug development, has equipped him with an unparalleled understanding of the scientific, regulatory, and commercial landscapes of the biopharmaceutical sector.

At Versant Ventures, Dr. Magni's investment focus is primarily on novel therapeutics and platform technologies within the life sciences. He is particularly interested in companies that are pioneering new approaches to treat serious diseases, leveraging his deep clinical insights to evaluate scientific merit and development potential. His involvement extends beyond capital investment, as he actively works with portfolio companies to refine their clinical strategies, navigate regulatory pathways, and build strong management teams.

Dr. Magni's influence can be seen in his involvement with several notable companies within Versant's portfolio. He has served on the boards of innovative firms such as Chinook Therapeutics (acquired by Novartis), Therachon (acquired by Pfizer), Monte Rosa Therapeutics, Black Diamond Therapeutics, and Quell Therapeutics, among others. These engagements highlight his commitment to fostering groundbreaking research and development that ultimately aims to bring transformative medicines to patients. His strategic vision and operational acumen are key assets in Versant Ventures' mission to support the next generation of biotech leaders.